Loading...
•
Dec 31, 2019
PTC Therapeutics Q4 2019 Earnings Report
PTC Therapeutics' financial performance for Q4 2019 was reported, showcasing revenue growth and strategic advancements.
Key Takeaways
PTC Therapeutics reported total revenues of $96.5 million for Q4 2019, compared to $86.3 million for Q4 2018. The company's net loss was $77.7 million for the quarter, compared to a net loss of $48.3 million for the same period in the previous year. The company reaffirms full year 2020 guidance.
Total revenues for the fourth quarter of 2019 were $96.5 million, up from $86.3 million in Q4 2018.
Translarna net product revenues were $48.4 million for the fourth quarter of 2019, compared to $56 million for the fourth quarter of 2018.
Emflaza net product revenues were $32.7 million for the fourth quarter of 2019, compared to $29.8 million for the fourth quarter of 2018.
GAAP R&D expenses were $81.8 million for the fourth quarter of 2019, compared to $53.6 million for the fourth quarter of 2018.
PTC Therapeutics
PTC Therapeutics
PTC Therapeutics Revenue by Segment
Revenue by Segment
Translarna Revenue
CapyFin.comEmflaza Revenue
CapyFin.com Forward Guidance
PTC reaffirms full year 2020 guidance. PTC anticipates full year DMD franchise net product revenues to be between $320 and $340 million. PTC anticipates GAAP R&D and SG&A expense for the full year 2020 to be between $610 and $640 million. PTC anticipates Non-GAAP R&D and SG&A expense for the full year 2020 to be between $545 and $575 million, excluding estimated non-cash, stock-based compensation expense of approximately $65 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income